TCP1 alpha/CCTA anticorps (full length)

N° du produit ABIN7879120

Cet anticorps anti-TCP1 alpha/CCTA Monoclonal Souris (Clone TP63-2428) (ABIN7879120) détecte spécifiquement TCP1 alpha/CCTA dans FACS et IHC (p). L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour TCP1 alpha/CCTA anticorps (full length) (ABIN7879120)

Antigène: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TCP1 alpha/CCTA est non-conjugé

Application: Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: TP63-2428

Détail du produit anti-TCP1 alpha/CCTA anticorps

Épitope: full length

Fonction: p63 Antibody

Purification: Protein G affinity chromatography

Immunogène: Full length human recombinant protein was used as the immunogen for the p63 antibody.

Isotype: IgG2b, kappa

Information d'application

Indications d'application: Optimal dilution of the p63 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store the p63 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur TCP1 alpha/CCTA

Antigène: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Autre désignation: p63

Sujet: P63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands, however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90 % . Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80 %. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

UniProt: Q9H3D4